Radicava Slows Decline in ALS Patients With Poorer Lung Function
Early treatment with Radicava (edaravone) significantly slows disability progression compared with a six-month delay, including in amyotrophic lateral…
Articles by Marta Figueiredo, PhD
Early CNM-Au8 Treatment Leads to Significant Survival Benefit in Study
Early use of Clene Nanomedicine’s experimental therapy CNM-Au8 reduces the risk of death by 70% in people with…
Potential Therapy ABBV-CLS-7262 Up Next for HEALEY Platform Trial
ABBV-CLS-7262, an experimental compound being developed by Calico Life Sciences and AbbVie for amyotrophic lateral sclerosis (ALS), will likely…
EU Awards €2.5M for Potential Vaccine for ALS Tied to C9orf72 Gene
A new €2.5 million (about $2.5 million) grant from the European Union (EU) will help advance a prototype vaccine for…
SBT-272, in Phase 1 Trial, Continues to Protect Motor Neurons in Mice
Stealth BioTherapeutics’ investigational therapy SBT-272 eased inflammation and upper motor neuron degeneration in a mouse model of amyotrophic lateral…
New Study Investigating Long-term Safety, Effectiveness of Reldesemtiv
A new study is investigating the longer-term effects — over a one-year period — of the therapy candidate reldesemtiv…
B12 Slows Functional Decline in Early-stage ALS, Data Show
Treatment with ultrahigh-dose methylcobalamin — the physiologically active form of vitamin B12 — effectively slowed functional decline in people with…
NU-9 Is Now AKV9, and Doing Well in Preclinical Studies
AKAVA Therapeutics’ experimental therapy AKV9, formerly NU-9, was superior to approved therapies for amyotrophic lateral sclerosis (ALS) at improving the…
Starting Tofersen Early Slows ALS Progression Better: Trial Data
Early use of Biogen’s tofersen significantly slows disability progression, as well as a decline in lung function, muscle strength, and…
FDA Pushes Decision on AMX0035 to September for Further Review
Note: This story was updated June 7, 2022, to note that CENTAUR is a Phase 2, not Phase 2/3,…